Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666744 | PMC |
| http://dx.doi.org/10.3389/fcimb.2023.1327413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An ATP-activated spatiotemporally controlled hydrogel prodrug system for treating multidrug-resistant bacteria-infected pressure ulcers.
Bioact Mater
March 2025
National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China.
Adenosine triphosphate (ATP)-activated prodrug approaches demonstrate potential in antibacterial uses. However, their efficacy frequently faces obstacles due to uncontrolled premature activation and spatiotemporal distribution differences under physiological circumstances. Herein, we present an endogenous ATP-activated prodrug system (termed ISD3) consisting of nanoparticles (indole-3-acetic acid/zeolitic imidazolate framework-8@polydopamine@platinum, IZPP) embedded in a silk fibroin-based hydrogel, aimed at treating multidrug-resistant (MDR) bacteria-infected pressure ulcers.
View Article and Find Full Text PDFEmerging phage-encoded endolysins to combat multidrug-resistant to boon prevent surgical site infection.
Ann Med Surg (Lond)
December 2024
AMR and Nanotherapeutics Lab, Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Science (SIMATS), Chennai, Tamil Nadu, India.
Comprised access to antibiotics - the growing problem of availability and responsible use.
Clin Microbiol Infect
December 2024
Division of Infectious Diseases & HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa; Faculty of Health and Medical Sciences, University of Liverpool, Liverpool, UK.
Revealing disparities in representation in knowledge generation and guideline development.
BMC Health Serv Res
November 2024
Harvard Medical School, Boston, USA.
Background: Multidrug-resistant tuberculosis (MDR/RR-TB) is a major global health challenge, disproportionately affecting low- and lower-middle-income countries (LLMICs). The World Health Organization (WHO) generates guidance to address the problem. Here, we explore the extent to which guidance and related knowledge are generated by experts living in the most-affected countries and consider the results in the context of the movement to decolonize global health.
View Article and Find Full Text PDFUpdated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?
IJTLD Open
November 2024
MACH Centre, Università di Milano, Milan, Italy.
In June 2024, WHO released 'Key updates to the treatment of drug-resistant tuberculosis: rapid communication', after the preliminary publication of results from two clinical trials: 'BEAT-Tuberculosis' and 'endTB'. All proposed regimens include clofazimine (Cfz). However, a recent paper has reported a high incidence of QTc prolongation among patients receiving Cfz-based treatment for multidrug-resistant TB in Taiwan.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!